ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer

Pharmacogenomics and Personalized Medicine

Volumn 4, Issue 1, 2011, Pages 47-63

  Vaezi, Alec ^a,b   Feldman, Chelsea H ^b   Niedernhofer, Laura J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Base excision repair; Chemotherapy; DNA damage; DNA repair; HNSCC; NSCLC; Nucleotide excision repair; Single nucleotide polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; PLATINUM COMPLEX; SCAFFOLD PROTEIN; TUMOR MARKER; XRCC1 PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHEMOSENSITIVITY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG RESPONSE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1 GENE; FUNCTIONAL GENOMICS; GENE EXPRESSION REGULATION; GENETIC IDENTIFICATION; GENETIC RISK; GENOTOXICITY; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; XRCC1 GENE;

EID: 83755228666     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol. 2007;4(2): 86-100.
3. Murdoch D. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review. Curr Opin Oncol. 2007;19(3):216-221.
4. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007;4(3):156-171.
5. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet. 2006;7(1):45-54.
6. Petermann E, Helleday T. Pathways of mammalian replication fork restart. Nat Rev Mol Cell Biol. 2010;11(10):683-687.
7. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross) linked to DNA repair. Cell. 2005;123(7):1191-1198.
8. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006;24(23):3799-3808.
9. Niedernhofer LJ, Garinis GA, Raams A, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature. 2006;444(7122):1038-1043.
10. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol. 2008;28(16): 5082-5092.
11. Bhagwat N, Olsen AL, Wang AT, et al. XPF-ERCC1 participates in the fanconi anemia pathway of cross-link repair. Mol Cell Biol. 2009;29(24):6427-6437.
12. Jaspers NG, Raams A, Silengo MC, et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am J Hum Genet. 2007;80(3):457-466.
13. Zwelling LA, Anderson T, Kohn KW. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 1979;39(2 Pt 1):365-369.
14. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001;2(8):483-490.
15. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291-1295.
16. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475-1485.
17. Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene. 2006;25(11):1612-1619.
18. Almeida KH, Sobol RW. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst). 2007;6(6):695-711.
19. Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair (Amst). 2003;2(9):955-969.
20. Lin Y, Hatem J, Wang J, Quinn A, Hicks D, Tang P. Tissue microarraybased immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast. Biotech Histochem. 2010 Aug 12. Epub ahead of print.
21. Tamaki K, Sasano H, Ishida T, et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci. 2010; 101(9):2074-2079.
22. Taillade L, Penault-Llorca F, Boulet T, et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol. 2007;18(6):1043-1050.
23. Babic A, Loftin IR, Stanislaw S, et al. The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods. 2010;52(4):287-300.
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-1184.
25. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N Engl J Med. 2007;356(24):2538-2540; author reply 2540-2531.
26. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 2000;89(5):453-457.
27. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356(8):800-808.
28. McGurk CJ, Cummings M, Koberle B, Hartley JA, Oliver RT, Masters JR. Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem. 2006;97(5):1121-1136.
29. Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng. 2007;9:289-320.
30. Schneider J, Classen V, Philipp M, Helmig S. Rapid analysis of XRCC1 polymorphisms using real-time polymerase chain reaction. Mol Cell Probes. 2006;20(3-4):259-262.
31. Fountzilas G, Kalogera-Fountzila A, Lambaki S, et al. MMP9 but not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol. 2009;2009:305908.
32. Matullo G, Dunning AM, Guarrera S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2006; 27(5):997-1007.
33. Ferte C, Andre F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol. 2010;7(7):367-380.
34. Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET. Translational Research Working Group developmental pathway for biospecimen- based assessment modalities. Clin Cancer Res. 2008;14(18): 5672-5677.
35. Ford BN, Ruttan CC, Kyle VL, Brackley ME, Glickman BW. Identification of single nucleotide polymorphisms in human DNA repair genes. Carcinogenesis. 2000;21(11):1977-1981.
36. Yu JJ, Mu C, Lee KB, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res. 1997; 382(1-2):13-20.
37. Yang M, Kim WH, Choi Y, et al. Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. Eur J Cancer Prev. 2006;15(3):269-273.
38. Okuda K, Sasaki H, Hikosaka Y, et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res. 2009 Sep 26. Epub ahead of print.
39. Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(2):491-496.
40. Yin J, Vogel U, Guo L, Ma Y, Wang H. Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population. Cancer Genet Cytogenet. 2006;164(1):66-70.
41. Hung RJ, Christiani DC, Risch A, et al. International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomarkers Prev. 2008;17(11): 3081-3089.
42. Yu D, Zhang X, Liu J, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res. 2008;14(9):2878-2886.
43. Deng Q, Sheng L, Su D, et al. Genetic polymorphisms in ATM, ERCC1, APE1 and iASPP genes and lung cancer risk in a population of southeast China. Med Oncol. 2010 Mar 31. Epub ahead of print.
44. Zienolddiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006; 27(3):560-567.
45. Ma H, Xu L, Yuan J, et al. Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics. 2007;17(6):417-423.
46. Shen M, Berndt SI, Rothman N, et al. Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China. Int J Cancer. 2005;116(5):768-773.
47. Jones NR, Spratt TE, Berg AS, Muscat JE, Lazarus P, Gallagher CJ. Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population. Cancer Epidemiol. 2011;35(2):175-181.
48. Li Y, Gu S, Wu Q, et al. No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur J Hum Genet. 2007;15(9):967-973.
49. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 2007;4(2):59-71.
50. Vineis P, Manuguerra M, Kavvoura FK, et al. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst. 2009;101(1):24-36.
51. Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis. 2000;21(8):1527-1530.
52. Sugimura T, Kumimoto H, Tohnai I, et al. Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med. 2006;35(1):11-18.
53. Abbasi R, Ramroth H, Becher H, Dietz A, Schmezer P, Popanda O. Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes. Int J Cancer. 2009;125(6):1431-1439.
54. Canova C, Hashibe M, Simonato L, et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res. 2009;69(7):2956-2965.
55. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2002;128(9):1084-1088.
56. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer. 2002;94(2):393-397.
57. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10(2):118-123.
58. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540-3546.
59. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005;11(4):1534-1538.
60. Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer. 2007;121(4):895-900.
61. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797-1803.
62. Vinolas N, Provencio M, Reguart N, et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer. 2011;71(2):191-198.
63. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair crosscomplementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy. Clin Cancer Res. 2004;10(15):4939-4943.
64. Park SY, Hong YC, Kim JH, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol. 2006;23(4):489-498.
65. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004; 44(3):311-316.
66. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007; 56(2):281-288.
67. Yin Z, Zhou B, He Q, et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer. 2009;9:439.
68. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15(8):1194-1203.
69. Zhou C, Ren S, Zhou S, et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol. 2010;40(10):954-960.
70. Li F, Sun X, Sun N, et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol. 2010; 33(5):489-494.
71. De las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabinetreated non-small-cell lung cancer patients. Ann Oncol. 2006;17(4): 668-675.
72. Wei SZ, Zhan P, Shi MQ, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and metaanalysis. Med Oncol. 2011;28(1):315-321.
73. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair crosscomplementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer. 2010;67(1):101-107.
74. Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol. 2006;24(26):4333-4339.
75. Grau JJ, Caballero M, Campayo M, et al. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope. 2009; 119(8):1484-1490.
76. Carles J, Monzo M, Amat M, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006; 66(4):1022-1030.
77. Wang X, Zhao J, Yang L, et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol. 2010; 27(2):484-490.
78. Vilmar A, Santoni-Rugiu E, Sorensen JB. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer. 2010;46(9):1554-1562.
79. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009;27(34):5808-5815.
80. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009;64(1):98-104.
81. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmall- cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983-991.
82. Lee HW, Choi YW, Han JH, et al. Expression of excision repair crosscomplementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65(3):377-382.
83. Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-smallcell lung cancer. Lung Cancer. 2008;59(3):377-384.
84. Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinumbased chemotherapy. Cancer Sci. 2007;98(9):1336-1343.
85. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol. 2009;64(3):565-573.
86. Holm B, Mellemgaard A, Skov T, Skov BG. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27(26):4254-4259.
87. Lee KH, Min HS, Han SW, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 2008;60(3):401-407.
88. Kang CH, Jang BG, Kim DW, et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer. 2010;68(3):478-483.
89. Koh Y, Jang B, Han SW, et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol. 2010;5(3):320-325.
90. Planchard D, Domont J, Taranchon E, et al. The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol. 2009;20(7):1257-1263.
91. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer. 2008;62(1):105-112.
92. Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol. 2010;21(9):1817-1824.
93. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer. 2010;70(1):63-70.
94. Doll CM, Prystajecky M, Eliasziw M, et al. Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol. 2010; 97(2):352-359.
95. Fountzilas G, Bamias A, Kalogera-Fountzila A, et al. Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res. 2009;29(2):529-538.
96. Koh Y, Kim TM, Jeon YK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2009;20(8): 1414-1419.
97. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007; 13(13):3855-3859.
98. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008; 99(1):167-172.
99. Shimizu J, Horio Y, Osada H, et al. MRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology. 2008;13(4):510-517.
100. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res. 2004;10(12 Pt 2):4215s-4219s.
101. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127(3):978-983.
102. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17(12):1818-1825.
103. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002; 8(7):2286-2291.
104. Ceppi P, Longo M, Volante M, et al. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol. 2008;3(6):583-589.
105. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007; 25(19):2747-2754.
106. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2(10):902-906.
107. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007;25(19):2741-2746.
108. Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol. 2010 May 14. Epub ahead of print.
109. Ren S, Zhou S, Zhang L, et al. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest. 2010;28(10):1078-1083.
110. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4731-4737.
111. Pers comm; 13th Annual Midwest DNA Repair Meeting, Toledo, Ohio, USA. Neha Baghwat, Laura J Niedernhofer, 2011.
112. Schneider J, Classen V, Bernges U, Philipp M. XRCC1 polymorphism and lung cancer risk in relation to tobacco smoking. Int J Mol Med. 2005;16(4):709-716.
113. Hao B, Miao X, Li Y, et al. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene. 2006; 25(25):3613-3620.
114. Hu Z, Ma H, Lu D, et al. A promoter polymorphism (-77T > C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics. 2005;15(7): 457-463.
115. Hsieh WC, Cheng YW, Lin CJ, Chou MC, Chen CY, Lee H. Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer. Jpn J Clin Oncol. 2009;39(2):81-85.
116. de Ruyck K, Szaumkessel M, de Rudder I, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res. 2007;631(2):101-110.
117. Ladiges W, Wiley J, MacAuley A. Polymorphisms in the DNA repair gene XRCC1 and age-related disease. Mech Ageing Dev. 2003; 124(1):27-32.
118. Cheng J, Leng S, Li H, et al. Suboptimal DNA repair capacity predisposes coke-oven workers to accumulate more chromosomal damages in peripheral lymphocytes. Cancer Epidemiol Biomarkers Prev. 2009; 18(3):987-993.
119. Abdel-Rahman SZ, El-Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett. 2000;159(1):63-71.
120. Relton CL, Daniel CP, Fisher A, Chase DS, Burn J, Tawn EJ. Polymorphisms of the DNA repair gene XRCC1 and the frequency of somatic mutations at the glycophorin A locus in newborns. Mutat Res. 2002;502(1-2):61-68.
121. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 1999;59(11):2557-2561.
122. Misra RR, Ratnasinghe D, Tangrea JA, et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett. 2003; 191(2):171-178.
123. Yin J, Vogel U, Ma Y, Qi R, Wang H. Association of DNA repair gene XRCC1 and lung cancer susceptibility among nonsmoking Chinese women. Cancer Genet Cytogenet. 2009;188(1):26-31.
124. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis. 2001;22(4):593-597.
125. Chen S, Tang D, Xue K, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis. 2002;23(8):1321-1325.
126. Improta G, Sgambato A, Bianchino G, et al. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case-control study in a Southern Italian population. Anticancer Res. 2008;28(5B):2941-2946.
127. Hung RJ, Brennan P, Canzian F, et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst. 2005;97(8):567-576.
128. Ratnasinghe D, Yao SX, Tangrea JA, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10(2):119-123.
129. Shen M, Berndt SI, Rothman N, et al. Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China. Anticancer Res. 2005;25(1B): 537-542.
130. Tanaka Y, Maniwa Y, Bermudez VP, et al. Nonsynonymous single nucleotide polymorphisms in DNA damage repair pathways and lung cancer risk. Cancer. 2010;116(4):896-902.
131. Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;56(2):153-160.
132. David-Beabes GL, London SJ. Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians. Lung Cancer. 2001;34(3):333-339.
133. Pachouri SS, Sobti RC, Kaur P, Singh J. Contrasting impact of DNA repair gene XRCC1 polymorphisms Arg399Gln and Arg194Trp on the risk of lung cancer in the north-Indian population. DNA Cell Biol. 2007;26(3):186-191.
134. Vogel U, Nexo BA, Wallin H, Overvad K, Tjonneland A, Raaschou-Nielsen O. No association between base excision repair gene polymorphisms and risk of lung cancer. Biochem Genet. 2004; 42(11-12):453-460.
135. Ito H, Matsuo K, Hamajima N, et al. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis. 2004;25(8):1395-1401.
136. Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, et al. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer. 2007;7:162.
137. Popanda O, Schattenberg T, Phong CT, et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis. 2004;25(12):2433-2441.
138. Ryk C, Kumar R, Thirumaran RK, Hou SM. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Cancer. 2006; 54(3):285-292.
139. Zhang X, Miao X, Liang G, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res. 2005;65(3):722-726.
140. Park JY, Lee SY, Jeon HS, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(1):23-27.
141. Zhou W, Liu G, Miller DP, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12(4):359-365.
142. Sreeja L, Syamala VS, Syamala V, et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol. 2008;134(6):645-652.
143. Divine KK, Gilliland FD, Crowell RE, et al. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res. 2001;461(4):273-278.
144. Applebaum KM, McClean MD, Nelson HH, Marsit CJ, Christensen BC, Kelsey KT. Smoking modif ies the relationship between XRCC1 haplotypes and HPV16-negative head and neck squamous cell carcinoma. Int J Cancer. 2009;124(11):2690-2696.
145. Csejtei A, Tibold A, Koltai K, et al. Association between XRCC1 polymorphisms and head and neck cancer in a Hungarian population. Anticancer Res. 2009;29(10):4169-4173.
146. Harth V, Schafer M, Abel J, et al. Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A. 2008;71(13/14):887-897.
147. Shen H, Sturgis EM, Khan SG, et al. An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Res. 2001;61(8):3321-3325.
148. Olshan AF, Watson MA, Weissler MC, Bell DA. XRCC1 polymorphisms and head and neck cancer. Cancer Lett. 2002;178(2):181-186.
149. Kowalski M, Przybylowska K, Rusin P, et al. Genetic polymorphisms in DNA base excision repair gene XRCC1 and the risk of squamous cell carcinoma of the head and neck. J Exp Clin Cancer Res. 2009;28:37.
150. Tae K, Lee HS, Park BJ, et al. Association of DNA repair gene XRCC1 polymorphisms with head and neck cancer in Korean population. Int J Cancer. 2004;111(5):805-808.
151. Sturgis EM, Castillo EJ, Li L, et al. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis. 1999;20(11):2125-2129.
152. Cho EY, Hildesheim A, Chen CJ, et al. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1100-1104.
153. Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope. 2005;115(12): 2221-2231.
154. Huang WY, Olshan AF, Schwartz SM, et al. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1747-1753.
155. Petty WJ, Knight SN, Mosley L, et al. A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced nonsmall cell lung cancer. J Thorac Oncol. 2007;2(3):197-202.
156. Wang Z, Xu B, Lin D, et al. XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer. 2008;62(1):99-104.
157. Yuan P, Liu L, Wu C, et al. No association between XRCC1 polymorphis and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy. Cancer Biol Ther. 2010:10(9).
158. Yoon SM, Hong YC, Park HJ, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(3):885-891.
159. Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer. 2009;65(2):230-236.
160. Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res. 2007;13(10):2876-2881.
161. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22(13):2594-2601.
162. Geisler SA, Olshan AF, Cai J, Weissler M, Smith J, Bell D. Glutathione S-transferase polymorphisms and survival from head and neck cancer. Head Neck. 2005;27(3):232-242.
163. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer. 2005;4(1):18.
164. Kang CH, Jang BG, Kim DW, et al. Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thorac Oncol. 2009;4(11): 1307-1312.
165. Nix P, Greenman J, Stafford N, Cawkwell L. Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Therapy. 2004(2):47-53.
166. Campioni M, Ambrogi V, Pompeo E, et al. Identification of genes down-regulated during lung cancer progression: a cDNA array study. J Exp Clin Cancer Res. 2008;27:38.
167. Jones NR, Spratt TE, Berg AS, Muscat JE, Lazarus P, Gallagher CJ. Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population. Cancer Epidemiol. 2010;35(2):175-81.
168. Varzim G, Monteiro E, Silva RA, Fernandes J, Lopes C. CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx. Eur J Cancer Prev. 2003;12(6):495-499.